Table 1.
Multiple sclerosis subjects | Healthy control subjects | |
---|---|---|
Sex, n (male/female) | 91 (35/56) | 72 (29/43) |
Age, years, mean ± SD | 46 ± 14 | 36 ± 12 |
EDSS score, median (range) | 2.5 (0–8) | – |
Disease course, RR/PMS | 62/29 | – |
Disease-modifying therapy (n) | Untreated (10) | – |
Interferon-beta (1) | ||
Glatiramer acetate (1) | ||
Dimethyl fumarate (13) | ||
Fingolimod (5) | ||
Natalizumab (2) | ||
Rituximab (10) | ||
Ocrelizumab (49) |
SD = standard deviation.